Stock Events

CureVac N.V. 

€3.27
0
+€0+0% Wednesday 14:38

Statistics

Day High
3.27
Day Low
3.27
52W High
5.44
52W Low
3.24
Volume
941
Avg. Volume
1,156
Mkt Cap
-
P/E Ratio
-
Dividend Yield
-
Dividend
-

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 1CVAC.MI. It's not an investment recommendation.

About

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. The company was founded in 2000 and is headquartered in Tübingen, Germany.
Show more...
CEO
Dr. Franz-Werner Haas L.L.M., LL.M., LLD, Ph.D.
Employees
764
Country
DE
ISIN
NL0015436031
WKN
000A2P71U

Listings